UNSPSC 41181538: Immunoglobulins a, g, m, d, and e immunological test system

In this classification, a Immunoglobulins a, g, m, d, and e immunological test system is a device that consists of the reagents used to identify by immunochemical techniques Immunoglobulins a, g, m, d, and e. US FDA regulates Immunoglobulins a, g, m, d, and e immunological test system under 21 CFR 866.5510 and under FDA product code DAH.

UNSPSC 41181538 Immunoglobulins A, G, M, D, and E immunological test system is a Commodity code, but recent state and local opportunities show minimal procurement activity aligned with this specific immunological testing scope. The code shows no direct demand for immunoglobulin-class serological test systems in the recent solicitation record. The few opportunities nominally tagged to this code involve broader laboratory services (specimen collection, general lab equipment maintenance, oil testing, water quality analysis, meter testing, and construction materials testing) that fall outside the clinical immunology or immunoglobulin analysis domain the code describes.

The source does not support evidence of regular state and local procurement under this Commodity code. Marion County, Oregon's July 2026 ITB for laboratory testing services and phlebotomy encompasses specimen collection and test reporting for adults in custody but does not specify immunoglobulin assays. Texas Department of State Health Services' July 2026 IFB for laboratory equipment repair covers sterilizers and washers unrelated to immunological testing. Subsequent opportunities—ranging from electric utility oil analysis and water treatment plant construction to transit authority charger maintenance and materials testing inspection—represent distinct commodity families. The mismatch between the code's nominal scope (immunoglobulin test systems) and the actual recent solicitations suggests either occasional misclassification by issuing bodies or extremely low procurement frequency for this specific test platform in state and local markets. Firms pursuing this code should verify the specific testing capabilities state and local public health labs are seeking, as the recent posting pattern offers little signal of active demand.